[go: up one dir, main page]

AR109376A1 - FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA - Google Patents

FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA

Info

Publication number
AR109376A1
AR109376A1 ARP170102053A ARP170102053A AR109376A1 AR 109376 A1 AR109376 A1 AR 109376A1 AR P170102053 A ARP170102053 A AR P170102053A AR P170102053 A ARP170102053 A AR P170102053A AR 109376 A1 AR109376 A1 AR 109376A1
Authority
AR
Argentina
Prior art keywords
formulations
hydroxibuty
modified
liberation
modified liberation
Prior art date
Application number
ARP170102053A
Other languages
English (en)
Inventor
Jean Dubuisson
- Guillard Herv Franois
Claire Mgret
Original Assignee
Flamel Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Ireland Ltd filed Critical Flamel Ireland Ltd
Publication of AR109376A1 publication Critical patent/AR109376A1/es

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulaciones de liberación modificada de g-hidroxibutirato. Usos terapéuticos.
ARP170102053A 2016-07-22 2017-07-21 FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA AR109376A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662365812P 2016-07-22 2016-07-22

Publications (1)

Publication Number Publication Date
AR109376A1 true AR109376A1 (es) 2018-11-28

Family

ID=64499936

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102053A AR109376A1 (es) 2016-07-22 2017-07-21 FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA

Country Status (1)

Country Link
AR (1) AR109376A1 (es)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12115142B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115143B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11766418B2 (en) 2016-07-22 2023-09-26 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12263151B2 (en) 2016-07-22 2025-04-01 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11826335B2 (en) 2016-07-22 2023-11-28 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11896572B2 (en) 2016-07-22 2024-02-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097176B2 (en) 2016-07-22 2024-09-24 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097175B2 (en) 2016-07-22 2024-09-24 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12109186B2 (en) 2016-07-22 2024-10-08 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115145B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115144B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12263150B2 (en) 2016-07-22 2025-04-01 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12128021B1 (en) 2016-07-22 2024-10-29 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12138239B2 (en) 2016-07-22 2024-11-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12144793B2 (en) 2016-07-22 2024-11-19 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12257223B2 (en) 2016-07-22 2025-03-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12239625B2 (en) 2016-07-22 2025-03-04 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186298B2 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226389B2 (en) 2016-07-22 2025-02-18 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226388B2 (en) 2016-07-22 2025-02-18 Flamel Ireland Limited Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics
US12226377B2 (en) 2019-03-01 2025-02-18 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12167992B2 (en) 2019-03-01 2024-12-17 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12167991B2 (en) 2019-03-01 2024-12-17 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12303478B2 (en) 2019-03-01 2025-05-20 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12295926B1 (en) 2022-02-07 2025-05-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Similar Documents

Publication Publication Date Title
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
UY37341A (es) Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
CY1124595T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
SV2018005683A (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos
ECSP17023281A (es) Inhibidores de mk2 y sus usos
EP3509581A4 (en) FORMULATIONS OF (R
DK3439635T3 (da) Formuleringer til behandling af fast tumor
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
ECSP17015977A (es) Terapia de combinacion
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CR20150524A (es) Compuestos de heteroarilo y sus usos
MX2016010296A (es) Compuestos farmaceutios.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
DK3400072T3 (da) Formuleringer til behandling af blærecancer
IL268728A (en) Formulations of cannabinoids for the treatment of acne
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
PT3206672T (pt) Formulações de libertação prolongada de anestésicos locais
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
FR3039396B1 (fr) Base de formulation cosmetique concentree

Legal Events

Date Code Title Description
FB Suspension of granting procedure